| human | Q5 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 311392946 |
| P496 | ORCID iD | 0000-0001-6763-0857 |
| P2038 | ResearchGate profile ID | Maartje_Hooning |
| P214 | VIAF ID | 292071049 |
| P10832 | WorldCat Entities ID | E39PBJwD6KXRjPYmxMh7Gfw9jC |
| P108 | employer | Erasmus MC | Q3126873 |
| P735 | given name | Maartje | Q18030899 |
| Maartje | Q18030899 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q36369415 | A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis |
| Q42676622 | A combined analysis of genome-wide association studies in breast cancer |
| Q34613513 | A genome-wide association scan on estrogen receptor-negative breast cancer |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q40050603 | Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis |
| Q36210166 | Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
| Q119213340 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q33747361 | BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q47418222 | Body weight and risk of breast cancer in BRCA1/2 mutation carriers |
| Q41195564 | Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q43639185 | Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriers |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q43425456 | Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study |
| Q46799385 | Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q33947829 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q31048641 | Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q51222361 | Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. |
| Q30660858 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer |
| Q38297766 | Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature |
| Q51187701 | Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. |
| Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
| Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| Q34613604 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q46247419 | Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q61970236 | Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors? |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q62583135 | Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q34114293 | Genome-wide association study identifies five new breast cancer susceptibility loci |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
| Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q38677974 | Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers |
| Q43677630 | Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q37692442 | Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q33646928 | Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q58597644 | Radiation Dose-Response For Risk Of Myocardial Infarction In Breast Cancer Survivors |
| Q37101570 | Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q51245901 | Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. |
| Q38717239 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers |
| Q46317196 | Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q33476082 | Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q35977371 | Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers |
| Q40173313 | Should we screen BRCA1 mutation carriers only with MRI? A multicenter study |
| Q34663394 | Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis |
| Q34113473 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy |
| Q51276495 | Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). |
| Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
| Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q33962070 | The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q90042753 | The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysis |
| Q34481713 | The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q30896495 | Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q41671579 | Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.